» Articles » PMID: 23200123

Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact

Overview
Journal Mol Cell
Publisher Cell Press
Specialty Cell Biology
Date 2012 Dec 4
PMID 23200123
Citations 595
Authors
Affiliations
Soon will be listed here.
Abstract

Histone lysine methylation has emerged as a critical player in the regulation of gene expression, cell cycle, genome stability, and nuclear architecture. Over the past decade, a tremendous amount of progress has led to the characterization of methyl modifications and the lysine methyltransferases (KMTs) and lysine demethylases (KDMs) that regulate them. Here, we review the discovery and characterization of the KMTs and KDMs and the methyl modifications they regulate. We discuss the localization of the KMTs and KDMs as well as the distribution of lysine methylation throughout the genome. We highlight how these data have shaped our view of lysine methylation as a key determinant of complex chromatin states. Finally, we discuss the regulation of KMTs and KDMs by proteasomal degradation, posttranscriptional mechanisms, and metabolic status. We propose key questions for the field and highlight areas that we predict will yield exciting discoveries in the years to come.

Citing Articles

Colorectal Cancer: Pathogenesis and Targeted Therapy.

Li J, Pan J, Wang L, Ji G, Dang Y MedComm (2020). 2025; 6(3):e70127.

PMID: 40060193 PMC: 11885891. DOI: 10.1002/mco2.70127.


Potential mechanism of circKIAA1429 accelerating the progression of hepatocellular carcinoma.

Yuan Y, Huang J, Wei G, Hu G, Yu H, Tao Y Infect Agent Cancer. 2025; 20(1):12.

PMID: 40025575 PMC: 11872318. DOI: 10.1186/s13027-025-00645-3.


Melatonin Modulates ZAP70 and CD40 Transcripts via Histone Modifications in Canine Ileum Epithelial Cells.

Hong J, Adam S, Wang S, Huang H, Kim I, Ahmed A Vet Sci. 2025; 12(2).

PMID: 40005847 PMC: 11860356. DOI: 10.3390/vetsci12020087.


Potent and selective SETDB1 covalent negative allosteric modulator reduces methyltransferase activity in cells.

Uguen M, Shell D, Silva M, Deng Y, Li F, Szewczyk M Nat Commun. 2025; 16(1):1905.

PMID: 39994194 PMC: 11850789. DOI: 10.1038/s41467-025-57005-3.


Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers.

Najia M, Jha D, Zhang C, Laurent B, Kubaczka C, Markel A bioRxiv. 2025; .

PMID: 39975048 PMC: 11838449. DOI: 10.1101/2025.01.31.635709.


References
1.
Herranz N, Dave N, Millanes-Romero A, Morey L, Diaz V, Lorenz-Fonfria V . Lysyl oxidase-like 2 deaminates lysine 4 in histone H3. Mol Cell. 2012; 46(3):369-76. DOI: 10.1016/j.molcel.2012.03.002. View

2.
Shi Y, Sawada J, Sui G, Affar E, Whetstine J, Lan F . Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature. 2003; 422(6933):735-8. DOI: 10.1038/nature01550. View

3.
Towbin B, Gonzalez-Aguilera C, Sack R, Gaidatzis D, Kalck V, Meister P . Step-wise methylation of histone H3K9 positions heterochromatin at the nuclear periphery. Cell. 2012; 150(5):934-47. DOI: 10.1016/j.cell.2012.06.051. View

4.
Jenuwein T . The epigenetic magic of histone lysine methylation. FEBS J. 2006; 273(14):3121-35. DOI: 10.1111/j.1742-4658.2006.05343.x. View

5.
Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield V . hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121(2):167-78. DOI: 10.1016/j.cell.2005.02.020. View